Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Registration Number
- NCT04224922
- Lead Sponsor
- AZ-VUB
- Brief Summary
This is a prospective Belgian, multi-center, open-label, single-arm phase II study of weekly paclitaxel at a dose of 80mg/m² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense epirubicin at a dose of 90 mg/m² and cyclophosphamide at a dose of 600 mg/m² every 2 weeks (plus Long acting GCSF at day 2) administrated preoperatively in locally advanced operable stage II and III triple negative breast cancer to evaluate tumor response in the breast and the axilla.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 63
-
Stage II-III operable triple negative (ER and PR < 10%; Her2 IHC 0-1 or FISH <2.0) breast cancer in women age > 18. For patients aged 65 or older the G8 geriatric screening test should be > 14 (on a total of 17).
-
Baseline mammography, US. MR of the breast on clinical indication.
-
FNA of suspicious axillary lymph node is indicated
-
Pre-treatment SN biopsy is indicated in clinical N0
-
Measurable loco-regional disease
-
Adequate bone marrow function, defined as
- Absolute neutrophil count(ANC) >1500*109/L
- Platelet count >100.000*109/L
-
Adequate liver function defined as
- Serum(total) bilirubin <1.5*upper limit of normal(ULN), unless the patient has documented Gilbert's Syndrome
- AST and/or ALT <2.5*ULN
- Alkaline phosphatase <2.5*ULN
-
Normal cardiac function measured by ultrasound with a left ventricular function > 55%
-
Creatinine clearance > 40 ml/min according to local laboratory standard (MDRD, CDK-epi, Cockroft-Gault, or other established formula to calculate renal function)
- T4d breast tumor
- Bilateral breast cancer
- Other invasive cancer in the past except for a localized squamous cell cancer or basal cell of the skin or an in situ squamous cell cancer of the cervix.
- Pregnant or lactating patients
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description single-arm Paclitaxel weekly paclitaxel at a dose of 80mg/m² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense epirubicin at a dose of 90 mg/m² and cyclophosphamide at a dose of 600 mg/m² every 2 weeks (plus Long acting GCSF at day 2) administrated preoperatively in locally advanced operable stage II and III triple negative breast cancer single-arm Carboplatinum weekly paclitaxel at a dose of 80mg/m² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense epirubicin at a dose of 90 mg/m² and cyclophosphamide at a dose of 600 mg/m² every 2 weeks (plus Long acting GCSF at day 2) administrated preoperatively in locally advanced operable stage II and III triple negative breast cancer single-arm Epirubicin weekly paclitaxel at a dose of 80mg/m² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense epirubicin at a dose of 90 mg/m² and cyclophosphamide at a dose of 600 mg/m² every 2 weeks (plus Long acting GCSF at day 2) administrated preoperatively in locally advanced operable stage II and III triple negative breast cancer single-arm Cyclophosphamide weekly paclitaxel at a dose of 80mg/m² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense epirubicin at a dose of 90 mg/m² and cyclophosphamide at a dose of 600 mg/m² every 2 weeks (plus Long acting GCSF at day 2) administrated preoperatively in locally advanced operable stage II and III triple negative breast cancer
- Primary Outcome Measures
Name Time Method -The rate of pCR in the breast and axilla (ypT0/is, ypN0) 20 weeks
- Secondary Outcome Measures
Name Time Method Evaluation of progression free survival 20 weeks Number of participants with treatment-related adverse events as assessed by CTCAE v.4.03 20 weeks Evaluation of breast-conserving surgery rate 20 weeks Evaluation of overall survival 20 weeks Evaluation of percentage of patients with BRCA1 or BRCA2 in this population. 20 weeks Evaluation of tumor infiltrating lymphocytes on the residual tumor 20 weeks Histopathological analysis of the lymphocyte infiltrate is performed on hematoxylin and eosin- stained sections of the core biopsies and afterwords on the resection specimen after neoadjuvant chemotherapy. Ancillary techniques and immunohistochemistry have no additional value upon this date, and are not recommanded. The overall assessment has to be made for the whole tumor area, regardless of hot spots. All mononuclear cells including lymphocytes and plasma cells should be scored (granulocytes and other polymorphonuclear leukocytes are excluded). The quantitative assessment of other mononuclear cells such as dendritic cells and macrophages is currently not recommended. TILs should be reported for the intratumoral lymphocytes (as first proposed by Denkert in 2010). Stromal lymphocytes (Str-Ly) are defined as the percentage of tumor stroma area that contains a lymphocytic infiltrate without direct contact to tumor cells.
Evaluation of the drug delivery 20 weeks Patient compliance for paclitaxel and carboplatin and for epirubicin and cyclophosphamide will be assessed by the investigator and/or study personnel at each patient visit. To accurately determine the patient's drug exposure throughout the study, the following information must be reported on the Drug Administration Record CRF pages and in the source document.
Planned dose administration, Actual total daily dose administrated, Regimen, Start and end date of drug administration, Dose change, Reason for dose changeEvaluation of clinical response rate (RECIST 1.1) by mammography and sonography in breast and axilla. 20 weeks genome analysis on tissue samples 20 weeks Tumor tissue samples (FFPE) for genetic research will be obtained from consenting patients both at screening and at surgery.
Genome analysis will be performed on (1) DNA extracted from EDTA blood (10ml) collected at the start of the treatment and (2) on DNA extracted from FFPE tumor tissue collected before the start of the neoadjuvant chemotherapy and after surgery.
Trial Locations
- Locations (18)
Onze Lieve Vrouw Ziekenhuis
🇧🇪Aalst, Belgium
Imelda Ziekenhuis
🇧🇪Bonheiden, Belgium
Universitaire Ziekenhuis Antwerpen
🇧🇪Edegem, Belgium
Cliniques Sud Luxembourg
🇧🇪Arlon, Belgium
St Lucas
🇧🇪Brugge, Belgium
AZ klina
🇧🇪Brasschaat, Belgium
Institut Jules Bordet
🇧🇪Brussels, Belgium
AZ Maria Middelares
🇧🇪Gent, Belgium
AZ St Lucas
🇧🇪Gent, Belgium
AZ Groeninge
🇧🇪Kortrijk, Belgium
UZ Leuven
🇧🇪Leuven, Belgium
CHR Citadelle
🇧🇪Liège, Belgium
CHU Sart-Tilman
🇧🇪Liège, Belgium
CMSE
🇧🇪Namur, Belgium
CHWAPI
🇧🇪Tournai, Belgium
CHU Mont-Godinne
🇧🇪Yvoir, Belgium
Clinique st Pierre
🇧🇪Ottignies, Belgium
CHR Verviers
🇧🇪Verviers, Belgium